Sheep Tick (Castor Bean Tick)

Ixodes ricinus — the sheep tick (also called the castor bean tick — for the engorged female's resemblance to a small castor bean) — is the EUROPEAN ANALOG of the deer tick (Ixodes scapularis — already in the Wild Files) and one of the most clinically important ticks in European medical entomology. The species is widespread across temperate Europe (the Mediterranean to Scandinavia, the British Isles to Russia) where it occurs in temperate broadleaf forest, scrubland, agricultural pasture, and other habitats with abundant deer, sheep, and other wild and domestic mammalian hosts. Adults are 3-4 mm long (engorged females reach 1 cm — the engorged female resembles a small castor bean, the source of the alternative common name). The species is the PRIMARY EUROPEAN VECTOR of LYME DISEASE — the disease caused by the spirochete bacterium BORRELIA BURGDORFERI sensu lato (a complex of related Borrelia species, including B. afzelii, B. garinii, and others that are more common in Europe than the strictly NA B. burgdorferi sensu stricto). Lyme disease in Europe causes initial symptoms (rash, fever, fatigue) followed by serious chronic complications affecting joints (Lyme arthritis), neurological function (Lyme neuroborreliosis), heart (Lyme carditis), and skin (acrodermatitis chronica atrophicans — a chronic skin condition particularly associated with European B. afzelii infections). Annual European Lyme disease incidence ranges from 65,000 to 200,000+ cases per year (estimates vary widely by surveillance methodology — the European CDC ECDC estimates ~85,000 cases per year as a conservative baseline, with actual incidence likely 2-5x higher due to underreporting). The species also transmits TICK-BORNE ENCEPHALITIS VIRUS (TBEV) — a flavivirus that causes a severe neurological illness with symptoms ranging from mild flu-like illness to severe meningoencephalitis with permanent neurological damage. European TBE incidence is approximately 10,000 cases per year (most concentrated in central and eastern European TBE-endemic regions including Austria, Germany, Czech Republic, Slovakia, the Baltic states, and Russia). TBE has effective VACCINE PROTECTION (approved TBE vaccines are widely used in TBE-endemic regions), but Lyme disease has no licensed vaccine for humans (a brief 1998-2002 NA Lyme vaccine LYMErix was discontinued; new Lyme vaccines are in clinical trials). The species is the focus of major European medical entomology research and ongoing public health monitoring through the European Centre for Disease Prevention and Control (ECDC). Climate change is driving NORTHWARD AND ALTITUDINAL EXPANSION of sheep tick range across Europe, expanding the geographic risk zones for Lyme disease and TBE. The species is harmless to humans without disease transmission but is a major medical concern in European outdoor recreation.